10-Q: Impact BioMedical Q1 2026 Results Show Increased Net Loss

Impact BioMedical reports a net loss of $2.28 million for Q1 2026, a significant increase from the prior year, primarily due to substantial stock-based compensation expenses.

Summary

• Impact BioMedical reported a net loss of $2,284,000 for the first quarter ended March 31, 2026, compared to a net loss of $1,278,000 for the same period in 2025.
• Total revenue for the quarter was $7,000, a new revenue stream from the Celios air purification technology acquired in February 2025.
• Total costs and expenses increased significantly to $2,296,000 from $1,010,000 in the prior year's quarter.
• The company's cash position improved to $20,000 from $3,000.
• The company continues to operate under substantial doubt regarding its ability to continue as a going concern.
• Management is exploring capital raises and monetization of intellectual property to address going concern issues.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to the significant increase in net loss, the dramatic rise in stock-based compensation, and the continued substantial doubt regarding the company's ability to continue as a going concern.

Positives

• Generated $7,000 in revenue from the new Celios air purification technology, marking the beginning of a new revenue stream.
• Cash and cash equivalents increased to $20,000 from $3,000.
• Interest income increased by 67% to $5,000, reflecting activity on notes receivable.
• The company has active development and licensing agreements for its technologies, including Linebacker and Equivir.

Negatives

• Net loss increased by 79% to $2,284,000 for the quarter ended March 31, 2026, compared to $1,278,000 in the prior year.
• Total costs and expenses more than doubled, increasing by 127% to $2,296,000.
• Stock-based compensation expense surged to $1,440,000 from $2,000 in the prior year, significantly contributing to the increased net loss.
• The company faces substantial doubt regarding its ability to continue as a going concern.
• Accounts receivable decreased to $0 from $5,000.
• Prepaid expenses and other current assets decreased to $95,000 from $142,000.
• Total current assets decreased to $377,000 from $411,000.
• Total assets decreased to $17,086,000 from $17,405,000.
• Total current liabilities increased to $1,687,000 from $1,162,000.
• Total liabilities increased to $2,375,000 from $1,850,000.
• Total stockholders equity decreased to $14,711,000 from $15,555,000.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern within one year of the financial statement issuance date due to operating losses and negative cash flows.
• The company's business model relies on partnerships and potential direct sales, with no guarantee of success.
• Failure to generate forecasted revenue from new products could result in non-cash impairment charges.
• The company is subject to risks inherent in establishing a new business enterprise, including possible delays in research, testing, and marketing efforts.
• The company's financial statements do not include adjustments that might be necessary if it cannot continue as a going concern.
• The company's disclosure controls and procedures were not effective as of March 31, 2026, indicating potential issues with timely and accurate reporting.

Future Outlook

The company's future outlook is uncertain due to its going concern status. Management is actively exploring options to raise capital, including potential equity raises and debt financing, and plans to monetize intellectual property and control operating costs to ensure continued operations.

Management Comments

• The company has incurred operating losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern.
• Management intends to take additional actions necessary to continue as a going concern, including monetization of intellectual properties and tightly controlling operating costs.
• The company is exploring several options to raise capital, including capital raises via its listing on the NYSE American and debt financing.

Industry Context

StockSavvy.ai notes that Impact BioMedical operates in the highly competitive and capital-intensive biopharmaceutical and healthcare sectors. The company's focus on novel technologies like Linebacker and Laetose positions it within emerging areas of oncology, inflammatory disorders, and metabolic diseases. However, the significant increase in stock-based compensation and the ongoing going concern issues are critical factors for investors to monitor in this dynamic industry.

Comparison to Industry Standards

• The company's revenue of $7,000 for the quarter is significantly below industry standards for established biopharmaceutical companies, highlighting its early-stage development.
• The substantial increase in stock-based compensation expense ($1,440,000) compared to revenue is a concern. While common in early-stage biotech for talent acquisition and retention, it heavily impacts net loss.
• The net loss of $2,284,000, while substantial, is not uncommon for pre-revenue or early-revenue stage biotech companies investing heavily in R&D. However, the lack of significant revenue growth and the going concern status are key differentiators.
• The company's cash position of $20,000 is critically low and far below the typical cash reserves maintained by companies in the sector to fund ongoing research, clinical trials, and operational expenses.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings.
• The company may become involved in legal proceedings arising in the ordinary course of business, which could have an adverse impact due to costs, diversion of resources, and negative publicity.

Related Party Transactions

• Amounts due to DSS, a related party, totaled $1,103,000 as of March 31, 2026, representing non-interest-bearing funding advances and shared expenses.
• The company incurred approximately $40,000 in related general and administrative expenses from DSS for the three months ended March 31, 2026.
• The company completed the acquisition of certain assets from DSS Pure Air, Inc. (a related party) on February 25, 2025, for $1,150,000 paid in company stock.

Stakeholder Impact

• Shareholders: The increased net loss and going concern status negatively impact shareholder value and confidence. Future capital raises could dilute existing shareholdings.
• Employees: Significant stock-based compensation may incentivize employees, but the company's financial precariousness could create job security concerns.
• Creditors: The going concern issue raises concerns about the company's ability to meet its financial obligations.
• Suppliers: Increased liabilities and potential cash flow issues could impact timely payments to suppliers.

Next Steps

• Continue to search for and evaluate potential new offerings to add to the company's portfolio.
• Pursue partnerships for further development and commercialization of technologies like Laetose and 3F.
• Explore options to raise capital, including equity raises and debt financing.
• Monetize intellectual properties.
• Tightly control operating costs.

Key Dates

Recommendation

The company's significant net loss, ongoing going concern issues, and reliance on future capital raises make it a high-risk investment. However, the development of new technologies and potential for future licensing revenue warrant a 'hold' recommendation for speculative investors, with a strong emphasis on monitoring cash burn and progress on capital raising efforts.

Keywords

Impact BioMedical, 10-Q, Quarterly Report, Biotech, Biopharmaceuticals, Healthcare, Wellness, Drug Discovery, Financial Results, Net Loss, Stock-based Compensation, Going Concern